Vera Therapeutics Presents Phase 2a Data Showing Atacicept Reduces Serum Gd-IgA1 in Patients with IgA Nephropathy at the American Society of Nephrology Kidney Week 2021
04 nov. 2021 16h05 HE
|
Vera Therapeutics
Phase 2a JANUS clinical trial showed atacicept administered subcutaneously once weekly demonstrated a durable and substantial reduction in serum galactose-deficient IgA1 (Gd-IgA1) in a dose-dependent...
Vera Therapeutics to Present Phase 2a Data on Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2021 Annual Meeting
13 oct. 2021 07h30 HE
|
Vera Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological...
Vera Therapeutics Hosting Key Opinion Leader Webinar on IgA Nephropathy
09 sept. 2021 07h30 HE
|
Vera Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological...
Vera Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
16 août 2021 07h30 HE
|
Vera Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological...
Vera Therapeutics Appoints Sean Grant as Chief Financial Officer
14 juil. 2021 07h30 HE
|
Vera Therapeutics
SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
24 juin 2021 07h15 HE
|
Vera Therapeutics
Completed an initial public offering with net proceeds, including the exercise of the underwriters’ option in full, of approximately $48.4 million in May 2021 - - -Expanded the management team to...
Vera Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
27 mai 2021 16h05 HE
|
Vera Therapeutics
SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Announces Pricing of Initial Public Offering
13 mai 2021 20h52 HE
|
Vera Therapeutics
SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a clinical-stage biotechnology company focused on developing and commercializing transformative...